US2006233894A1PendingUtilityA1

Anti-Inflammatory Humate Compositions and Methods of Use Thereof

53
Individually held — no corporate assignee on recordPriority: Jan 3, 2003Filed: Apr 14, 2006Published: Oct 19, 2006
Est. expiryJan 3, 2023(expired)· nominal 20-yr term from priority
Inventors:John F. LownKevin GillStephen CutlerHorace G. CutlerStanley H. Pollock
A61K 31/405
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure relates to an anti-inflammatory composition containing humate, such as insoluble, granular, other insoluble, or soluble humate, particularly Menefee Humate®. The disclosure also includes other anti-inflammatory compositions containing humate and at least one additional anti-inflammatory agent such as indomethacin or another nonsteroidal anti-inflammatory drug. The disclosure includes a method of treating acute or chronic inflammation in an animal, including a human, by administering one of these compositions. A method of facilitating the therapeutic effect of a therapeutic drug in an animal by co-administering humate is also provided.

Claims

exact text as granted — not AI-modified
1 . An anti-inflammatory composition comprising: 
 humate as a primary anti-inflammatory agent; and    a pharmaceutically acceptable carrier.    
   
   
       2 . The composition of  claim 1 , wherein the humate is prehistoric humate.  
   
   
       3 . The composition of  claim 2 , wherein the humate is derived from the Menefee Geological Formation in N. Mex.  
   
   
       4 . The composition of  claim 1 , wherein the humate comprises at least 50% humic acids.  
   
   
       5 . The composition of  claim 1 , wherein the composition is for oral or topical administration and the humate is insoluble, granular humate.  
   
   
       6 . The composition of  claim 1 , wherein the composition is for injection administration and the humate is soluble.  
   
   
       7 . The composition of  claim 1 , wherein the humate comprises between approximately 0.1% and 1.0% by weight of the composition.  
   
   
       8 . The composition of  claim 7 , wherein the humate comprises approximately 0.1- 0.5% by weight of the composition.  
   
   
       9 . The composition of  claim 1 , wherein humate constitutes the sole anti-inflammatory agent.  
   
   
       10 . The composition of  claim 9 , wherein at least one additional anti-inflammatory agent is a nonsteroidal anti-inflammatory drug.  
   
   
       11 . The composition of  claim 10 , wherein the nonsteroidal anti-inflammatory drug is an indole derivative.  
   
   
       12 . The composition of  claim 11 , wherein the nonsteroidal anti-inflammatory drug is indomethacin.  
   
   
       13 . A method of reducing inflammation in a tissue of an animal comprising supplying a composition containing humate as a primary anti-inflammatory agent to the tissue through oral, topical or injection administration.  
   
   
       14 . The method of  claim 13 , wherein the humate is supplied orally and constitutes approximately 0.1 to 0.5% by weight of the total food consumed by the animal.  
   
   
       15 . The method of  claim 13 , wherein the method comprises supplying a composition containing humate as the sole anti-inflammatory agent.  
   
   
       16 - 20 . (canceled)  
   
   
       21 . The method of  claim 13 , wherein the composition containing humate is supplied orally and wherein the humate constitutes approximately 0.1- 0.5% by weight of the animal's food intake  
   
   
       22 . The method of  claim 13 , wherein the animal is a human.  
   
   
       23 . The method of  claim 13 , wherein the inflammation is acute.  
   
   
       24 . The method of  claim 13 , wherein the inflammation is chronic.  
   
   
       25 . The method of  claim 24 , wherein the inflammation is a result of arthritis.  
   
   
       26 - 31 . (canceled)

Join the waitlist — get patent alerts

Track US2006233894A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.